Having established that IL2RB+ T-cells in CRC are associated with immune-checkpoint expression, we investigated whether IL2RB may have utility as a predictive biomarker for CRC patients receiving immune-checkpoint blockade therapy. Here, IL2RB is linked to colorectal carcinoma.